证券代码：688202 证券简称：美迪西 公告编号：2025-062 上海美迪西生物医药股份有限公司 关于开立募集资金专户并签署募集 资金专户存储三方监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）于2023年2月7日出具的《关于同意上海美迪西 生物医药股份有限公司向特定对象发行股票注册的批复》（证监许可[2023]265号），同意上海美迪西 生物医药股份有限公司（以下简称"公司"）向特定对象发行A股股票的注册申请。截至2023年8月4日 止，公司募集资金总额人民币100,000.00万元，扣除承销保荐费等各项发行费用1,470.93万元（不含增值 税）后，实际募集资金净额为人民币98,529.07万元。立信会计师事务所（特殊普通合伙）对公司向特定 对象发行A股股票的资金到位情况进行了审验，并出具了《上海美迪西生物医药股份有限公司验资报 告》（信会师报字[2023]第ZA14977号）。募集资金到账后，已全部存放于募集资金专项账户内， ...

Core Insights - A block trade of 100,000 shares of Meidisi occurred on September 24, with a transaction value of 5.48 million yuan and a transaction price of 54.80 yuan, representing a discount of 21.39% compared to the closing price of the day [1] Trading Activity - The total transaction amount for the two block trades in the last three months reached 13.80 million yuan [1] - The closing price of Meidisi on the same day was 69.71 yuan, reflecting an increase of 1.96% [1] - The daily turnover rate was 3.94%, with a total trading volume of 364 million yuan [1] - There was a net outflow of 22.39 million yuan in main capital for the day, and the stock has declined by 8.28% over the past five days, with a total net outflow of 215 million yuan [1] Margin Trading Data - The latest margin financing balance for Meidisi is 460 million yuan, which has decreased by 33.86 million yuan over the past five days, representing a decline of 6.86% [1]

对应的募集资金专项账户，用于"海外营销及研发中心项目"募集资金的存储和 使用；同意《关于部分募投项目终止并将剩余募集资金投入新项目、永久补充流 动资金及继续存放在募集资金专户的议案》经股东大会审议通过后，授权公司管 理层及其授权人士全权办理开立募集资金专户、签订募集资金专户监管协议等相 关事项。2025 年 9 月 15 日，《关于部分募投项目终止并将剩余募集资金投入新 项目、永久补充流动资金及继续存放在募集资金专户的议案》已经公司 2025 年 第二次临时股东大会审议通过。 为规范公司募集资金管理和使用，保护投资者的权益，根据《上市公司募集 资金监管规则》和《上海证券交易所科创板上市公司自律监管指引第 1 号——规 范运作》等相关法规及公司募集资金管理制度等规定，公司与保荐机构广发证券 股份有限公司（以下简称"广发证券"）以及相关募集资金存储银行签署了募集 资金专户存储三方监管协议。前述协议与上海证券交易所制定的《募集资金专户 存储三方监管协议（范本）》不存在重大差异。 三、募集资金专户存储三方监管协议的主要内容 证券代码：688202 证券简称：美迪西 公告编号：2025-062 上海美迪西生物医药股份有 ...

上海美迪西生物医药股份有限公司 2025 年员工持股计划第一次持有人会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、会议召开情况 上海美迪西生物医药股份有限公司（以下简称"公司"）2025 年员工持股计 划（以下简称"本次员工持股计划"）第一次持有人会议于 2025 年 9 月 24 日以 现场结合通讯方式召开。本次会议由公司董事会秘书卓楠女士召集并主持，出席 本次会议的持有人共 126 人，代表公司 2025 年员工持股计划份额 14,677,719 份， 占公司 2025 年员工持股计划已认购总份额（不含预留部分）的 87.44%。本次会 议的召集、召开和表决程序符合有关法律、行政法规、部门规章和《上海美迪西 生物医药股份有限公司 2025 年员工持股计划（草案）》（以下简称《" 2025 年员工 持股计划（草案）》"）及《上海美迪西生物医药股份有限公司 2025 年员工持股 计划管理办法》（以下简称"《2025 年员工持股计划管理办法》"）等有关规定。 会议审议通过了如下议案： 二、会议审议情况 证 ...

Group 1 - The core viewpoint of the articles highlights the recent performance and financial metrics of Medisi, indicating a significant increase in stock price and fluctuations in trading volume [1][2] - As of September 24, Medisi's stock price rose by 2.03% to 69.76 CNY per share, with a total market capitalization of 9.372 billion CNY [1] - Year-to-date, Medisi's stock has increased by 131.22%, with a recent decline of 8.21% over the last five trading days [1] Group 2 - Medisi operates in the pharmaceutical and biotechnology sector, specifically in medical research outsourcing, and is involved in various concept sectors including CRO and AI medicine [2] - For the first half of 2025, Medisi reported a revenue of 540 million CNY, reflecting a year-on-year growth of 3.64%, while the net profit attributable to shareholders was -12.8984 million CNY, showing an increase of 81.63% compared to the previous period [2] - The company has distributed a total of 158 million CNY in dividends since its A-share listing, with 33.9365 million CNY distributed over the past three years [3]

南方财经9月23日电，美迪西发布声明称，鸿绪生物近日在微信公众号"鸿绪生物"上就与公司诉讼案件 公开发布《鸿绪生物关于依法对美迪西提起诉讼的声明》的文章。鸿绪生物在文章中所述内容与客观事 实严重不符。因涉及合同的签署、履行细节及违约责任的认定等，均为诉讼案件核心争议，有待人民法 院依法查明后予以公布。美迪西在声明中称，公司已全面、适当地履行了合同义务，截至本声明发布之 日，鸿绪生物尚有人民币55.76万元合同尾款未向公司支付，公司保留通过一切合法途径追偿的权利。 ...

文 | 《BUG》栏目 刘丽丽 鸿绪生物医药科技（北京）有限公司（以下简称"鸿绪生物"）近期发表声明，对有关美迪西普亚医药科 技（上海）有限公司诉讼的情况进行说明。 声明称，美迪西的履约行为未能达到合同与行业应有标准，导致项目和公司蒙受严重损失。因此，鸿绪 生物不得不依法向人民法院提起诉讼。目前，法院已冻结了美迪西的银行账户（财产保全）。 鸿绪生物要求判令美迪西普亚向鸿绪生物支付合同解除以前延期履行合同的违约金、返还已支付服务 费、赔偿原告各项损失等，合计约1.59亿元，其中要求赔偿原告各项损失1.5亿元。 根据财报，美迪西处于亏损状态，今年利润总额-0.21亿元，归母净利润-0.13亿元，归母扣非净利 润-0.27亿元。对于诉讼相关问题，《BUG》栏目多次拨打美迪西董秘电话，但电话被转接后自动挂 断。 美迪西交付滞后被诉，鸿绪生物称"蒙受严重损失" 在这场纠纷中，美迪西的角色是CRO（医药外包）企业，也就是医药研发合同外包服务机构，曾被认 定为上海市科技"小巨人"企业。 公开资料显示，目前中国制药公司的研发与注册能力，可以分为：强研发强注册、强研发弱注册、弱研 发强注册、弱研发弱注册、无研发和注册等五种类型 ...

Company Overview - Medisi, established on February 2, 2004, and listed on November 5, 2019, is located in Shanghai and provides comprehensive new drug research and development services for pharmaceutical companies and other new drug research institutions [1] - The company's main business revenue composition includes: preclinical research 50.34%, drug discovery and pharmaceutical research 49.64%, and others 0.01% [1] Financial Performance - For the first half of 2025, Medisi achieved operating revenue of 540 million yuan, representing a year-on-year growth of 3.64% [2] - The net profit attributable to the parent company was -12.89 million yuan, showing a year-on-year increase of 81.63% [2] - Since its A-share listing, Medisi has distributed a total of 158 million yuan in dividends, with 33.94 million yuan distributed over the past three years [3] Stock Performance - As of September 19, Medisi's stock price was 74.38 yuan per share, with a market capitalization of 9.993 billion yuan [1] - Year-to-date, the stock price has increased by 146.54%, but it has decreased by 5.43% in the last five trading days [1] - The stock has appeared on the "龙虎榜" (a stock trading list) three times this year, with the most recent net purchase of 102 million yuan on July 17 [1] Shareholder Information - As of June 30, Medisi had 12,900 shareholders, an increase of 3.94% from the previous period, with an average of 10,443 circulating shares per shareholder, a decrease of 3.79% [2] Industry Classification - Medisi belongs to the pharmaceutical and biological industry, specifically in the medical services and medical research outsourcing sector [2]

Core Insights - The conference highlighted the growing global competitiveness of Chinese innovative drugs, particularly in areas like ADC and bispecific antibodies, while emphasizing the need for improvement in original innovation capabilities [1][5][6] - There is a consensus among industry leaders that "going global" is essential for the future of Chinese innovative drugs, with calls for more supportive policies to facilitate this process [1][7][9] Group 1: Current State of Chinese Innovative Drugs - Chinese innovative drugs have reached a global competitiveness level from "1 to 10," especially in engineering fields, but still need to enhance original innovation from "0 to 1" [1] - The quality of projects is crucial for international expansion, as highlighted by industry leaders who stress that strong data and comprehensive packages are essential for success [2][3] - The past decade has seen significant development in the Chinese innovative drug ecosystem, with a complete industrial chain now in place, particularly in cities like Shanghai [4] Group 2: Challenges and Opportunities - The domestic market's limitations are pushing companies to explore international markets, with a focus on countries involved in the Belt and Road Initiative [7] - There is a need for policy reforms regarding listing standards to support innovative drug companies that face long development cycles and high R&D costs [7][9] - The current pricing of innovative drugs in international markets is still influenced by domestic prices, which poses challenges for global competitiveness [9] Group 3: Future Directions and Innovations - The industry is witnessing a surge in various therapeutic areas, including small molecules, antibodies, peptides, RNA, and gene therapies, indicating a diverse landscape of innovation [10] - The potential for small nucleic acids and other novel therapies is recognized as a significant opportunity for Chinese companies to lead in the global market [10] - Industry leaders express confidence in the future of Chinese innovative drugs, anticipating that with time, more companies will emerge as global players [11]

作为科创板迈向"新高地"暨"硬科硬客"2025年会的重要内容之一，9月10日，君实生物（688180.SH）、 皓元医药（688131.SH）、药康生物（688046.SH）、美迪西（688202.SH）、迈威生物（688062.SH） 等科创板创新药领域龙头上市公司高管，逾50家机构投资者参与了创新药产业链的高层次闭门研讨会。 会议围绕中国创新药出海的核心能力、国际竞争力现状及未来发展方向进行深入研讨。 与会嘉宾认为，中国创新药已具备从"1到10"的全球竞争力，尤其在ADC、双抗等工程化领域国际领 先，但在"0到1"的原始创新方面仍需努力。出海，成为行业共识，企业呼吁政策进一步支持破解"出 海"难题。 "君实生物是最早把国际化当作自己重要战略的本土企业之一，特瑞普利单抗也是第一个获得美国FDA 批准上市的中国自研自产PD-1产品，目前已经在40个国家和地区获批。"李鑫坦言，产品出海是高成本 的事情，需要满足国际上未被满足的需求，同时要应对FDA等海外监管机构的严格审评，包括临床和生 产端。 皓元医药董事长兼总经理郑保富从产业链角度分析："创新药是我们CRO（定制研发机构）、CDMO （医药合同定制研发生产企 ...